搜索临床试验以:AZD4017
总计83个结果
-
Samsung Medical Center撤销
-
National Cancer Institute (NCI)完全的造血和淋巴细胞肿瘤 | 晚期淋巴瘤 | 晚期恶性实体瘤 | 难治性淋巴瘤 | 难治性恶性实体瘤 | 难治性浆细胞骨髓瘤美国
-
Massachusetts General HospitalUnited States Department of Defense; AstraZeneca完全的
-
AstraZeneca终止
-
Samsung Medical CenterAstraZeneca终止
-
AstraZenecaNational Institutes of Health (NIH); Eolas Therapeutics INC.完全的
-
Massachusetts General HospitalNational Cancer Institute (NCI); AstraZeneca主动,不招人
-
AstraZeneca撤销核心:复发或难治性弥漫性大 B 细胞淋巴瘤 | 模块 1:非 GCB 弥漫性大 B 细胞淋巴瘤
-
Royal Marsden NHS Foundation TrustAstraZeneca; Institute of Cancer Research, United Kingdom完全的
-
Canadian Cancer Trials GroupAstraZeneca完全的
-
AstraZeneca完全的
-
Cambridge University Hospitals NHS Foundation TrustAstraZeneca完全的
-
Imperial College LondonAstraZeneca; Medical Research Council; National Institute for Health Research, United Kingdom完全的
-
University of BirminghamPfizer; AstraZeneca; Mirati Therapeutics Inc.; Cancer Research UK; Experimental Cancer Medicine Centres主动,不招人
-
UNICANCERAstraZeneca; Intergroupe Francophone de Cancerologie Thoracique; Fondation ARC完全的
-
Queen Mary University of LondonAstraZeneca; Cancer Research UK未知鳞状细胞肺癌 | 三阴性乳腺癌 | 具有 KRAS 突变的非鳞状细胞肺癌 | 具有野生型 KRAS 的非鳞状细胞肺癌英国
-
Southwest Oncology GroupNational Cancer Institute (NCI)完全的复发性鳞状细胞肺癌 | IV 期鳞状细胞肺癌 AJCC v7 | FGFR1 基因扩增 | FGFR2 基因扩增 | FGFR2基因突变 | FGFR3基因突变 | FGFR1基因突变 | FGFR3 基因扩增美国, 加拿大
-
Queen Mary University of LondonAstraZeneca; Cancer Research UK终止